1-甲基-4-(s-三氟甲基-[1,3,4]噻二唑-z-基)哌嗪 | 57709-34-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-甲基-4-(s-三氟甲基-[1,3,4]噻二唑-z-基)哌嗪
• 英文名称: Piperazine, 1-methyl-4-(5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl)-
• 英文别名: 2-(4-methylpiperazin-1-yl)-5-(trifluoromethyl)-1,3,4-thiadiazole
• CAS: 57709-34-9
• 化学式: C₈H₁₁F₃N₄S
• 分子量: 252.26
• InChiKey: QJSFDLRMJWUTTC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  60.5
• 氢给体数：
  0
• 氢受体数：
  8

文献信息

• 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS
  申请人：Shipps, JR. Gerald W.

  公开号：US20100130465A1

  公开（公告）日：2010-05-27

  The present invention relates to novel Anilinopiperazine Derivatives of formula (I), compositions comprising the Anilinopiperazine Derivatives, and methods for using the Anilinopiperazine Derivatives for treating or preventing a proliferative disorder, an anti-proliferative disorder, inflammation, arthritis, a central nervous system disorder, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral disease, a fungal infection, or a disorder related to the activity of a protein kinase.

  本发明涉及一种新型的Anilinopiperazine衍生物的公式(I)，包括该Anilinopiperazine衍生物的组合物，并且使用该Anilinopiperazine衍生物治疗或预防增生性疾病、抗增生性疾病、炎症、关节炎、中枢神经系统疾病、心血管疾病、脱发、神经疾病、缺血性损伤、病毒性疾病、真菌感染或与蛋白激酶活性相关的疾病的方法。
• Aminobenzoquinazolinone M1 Receptor Positive Allosteric Modulators
  申请人：Kuduk Scott D.

  公开号：US20120264761A1

  公开（公告）日：2012-10-18

  The present invention is directed to aminobenzoquinazolinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及式(I)的氨基苯并喹唑酮化合物，它们是M1受体正向变构调节剂，可用于治疗M1受体参与的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍。本发明还涉及包含该化合物的制药组合物，以及在治疗M1受体介导的疾病中使用该化合物和组合物的方法。
• AMINOBENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2515656B1

  公开（公告）日：2014-08-06
• US8318735B2
  申请人：——

  公开号：US8318735B2

  公开（公告）日：2012-11-27
• US8383638B2
  申请人：——

  公开号：US8383638B2

  公开（公告）日：2013-02-26